Novel cell therapy treatments offer promise to immune-compromised children
Retrieved on:
星期四, 四月 18, 2024
Sickle cell disease, University, Cancer, Disorder, Nature Communications, Immunodeficiency, Pediatric Transplantation, Hope, Hospital, CCIR, Food, Blood, Regenerative medicine, Intermountain, Cytomegalovirus, Huntsman Cancer Institute, Cell, Research, Infant, Bollard, VST, DRS, Epstein–Barr virus, Patient, Anemia, Haematopoietic system, Virus, Faculty, Malignancy, Infection, Good, Immune system, GMP, Clinical trial, Viral, Vaccine
Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.
Key Points:
- Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.
- , the paper’s first author and the Translational Research Laboratory director at the Children’s National Cell Enhancement and Technologies for Immunotherapy (CETI) program.
- They combined the expertise at Children’s National in producing and banking cell therapy products with the community built around the PTCTC.
- In the decade ahead, Dr. Bollard sees promise in cell therapies for patients with cancer, immune deficiencies after transplant and dozens of other disorders, including genetic and autoimmune diseases.